Primakov, Sergey P. http://orcid.org/0000-0002-3856-9740
Ibrahim, Abdalla http://orcid.org/0000-0003-4138-5755
van Timmeren, Janita E. http://orcid.org/0000-0002-8166-6853
Wu, Guangyao
Keek, Simon A.
Beuque, Manon http://orcid.org/0000-0001-6804-5908
Granzier, Renée W. Y. http://orcid.org/0000-0003-1398-7249
Lavrova, Elizaveta http://orcid.org/0000-0003-2751-790X
Scrivener, Madeleine
Sanduleanu, Sebastian
Kayan, Esma
Halilaj, Iva http://orcid.org/0000-0002-7805-7918
Lenaers, Anouk http://orcid.org/0000-0001-7354-7355
Wu, Jianlin
Monshouwer, René http://orcid.org/0000-0002-9611-3901
Geets, Xavier
Gietema, Hester A. http://orcid.org/0000-0001-6077-1446
Hendriks, Lizza E. L. http://orcid.org/0000-0002-3521-2535
Morin, Olivier http://orcid.org/0000-0002-9240-5704
Jochems, Arthur
Woodruff, Henry C. http://orcid.org/0000-0001-7911-5123
Lambin, Philippe http://orcid.org/0000-0001-7961-0191
Article History
Received: 11 March 2021
Accepted: 9 May 2022
First Online: 14 June 2022
Competing interests
: S.P.P. reports, within the submitted work a non-issue, non-licensed patent in the field of medical imaging segmentation: IMAGE DATA PROCESSING METHOD, METHOD OF TRAINING A MACHINE LEARNING DATA PROCESSING MODEL, AND IMAGE PROCESSING SYSTEM; the year 2020; application number (PCT/NL2020/050794); inventors: S.P.P., H.C.W., P.L. reports, within and outside the submitted work, during the last 5 years, grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic, Health Innovation Ventures and Exomnis. He received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in-kind manpower contribution from Oncoradiomics, BHV, Merck, Accuray, Elekta and Convert pharmaceuticals. Dr. Lambin has minority shares in the company Oncoradiomics SA, Comunicare Solutions SA, LivingMed Biotech, and Convert pharmaceuticals and is co-inventor of two issued patents with royalties on radiomics (METHOD AND SYSTEM FOR DETERMINING A PHENOTYPE OF A NEOPLASM IN A HUMAN OR ANIMAL BODY; the year 2014; publication number WO/2014/171830; IMAGE ANALYSIS METHOD SUPPORTING ILLNESS DEVELOPMENT PREDICTION FOR A NEOPLASM IN A HUMAN OR ANIMAL BODY; the year 2016; publication number WO/2016/060557) licensed to Oncoradiomics, one issue patent on mtDNA (METHOD FOR DETERMINING THE RISK OF DEVELOPING RADIATION-INDUCED TOXICITY AFTER EXPOSURE TO RADIATION; the year 2014; publication number WO/2014/184028) licensed to ptTheragnostic/DNAmito, three non-patentable inventions (software) licensed to ptTheragnostic/ DNAmito, Oncoradiomics, and Health Innovation Ventures. He confirms that none of the above entities or funding was involved in the preparation of this paper. Dr. Woodruff reports, outside of the current manuscript, (minority) shares in the company Oncoradiomics and non-issues, the non-licensed patent in the field of medical imaging segmentation. Dr. Lizza Hendriks reports, none related to the current manuscript, outside of current manuscript: research funding Roche Genentech, Boehringer Ingelheim, AstraZeneca (all institution); advisory board: Boehringer, BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Boehringer Ingelheim, Amgen (all institution); speaker: MSD (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Quadia (self); interview sessions funded by Roche Genentech (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD /Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati. The remaining authors declare no competing interests.